

Melissa Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8212249/publications.pdf>

Version: 2024-02-01

56
papers

2,050
citations

304602

22
h-index

243529

44
g-index

58
all docs

58
docs citations

58
times ranked

3247
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 49-62.	1.1	31
2	Serotoninâ€Affecting Antidepressant Use in Relation to Platelet Reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 909-918.	2.3	9
3	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. <i>Pathology</i> , 2022, 54, 746-754.	0.3	2
4	Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet function. <i>Haematologica</i> , 2021, 106, 1423-1432.	1.7	7
5	Proteome and functional decline as platelets age in the circulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3095-3112.	1.9	23
6	Platelet inhibition by P2Y₁₂ antagonists is potentiated by adenosine signalling activators. <i>British Journal of Pharmacology</i> , 2021, 178, 4758-4771.	2.7	7
7	A novel genetic variant in <i>PTGS1</i> affects Nâ€glycosylation of cyclooxygenaseâ€1 causing a dominantâ€negative effect on platelet function and bleeding diathesis. <i>American Journal of Hematology</i> , 2021, 96, E83-E88.	2.0	2
8	Hypoxia Modulates Platelet Purinergic Signalling Pathways. <i>Thrombosis and Haemostasis</i> , 2020, 120, 253-261.	1.8	12
9	Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> , 2020, 142, S469-S523.	1.6	486
10	Profiling the eicosanoid networks that underlie the antiâ€and proâ€thrombotic effects of aspirin. <i>FASEB Journal</i> , 2020, 34, 10027-10040.	0.2	10
11	Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age. <i>Circulation Research</i> , 2020, 127, 394-396.	2.0	3
12	Loss of GPVI and GPIbâ€ contributes to trauma-induced platelet dysfunction in severely injured patients. <i>Blood Advances</i> , 2020, 4, 2623-2630.	2.5	29
13	Combination of cyclic nucleotide modulators with P2Y 12 receptor antagonists as antiâ€platelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1705-1713.	1.9	3
14	2019 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> , 2019, 140, e904-e914.	1.6	33
15	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). <i>British Journal of Pharmacology</i> , 2019, 176, 988-999.	2.7	49
16	A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding. <i>Blood</i> , 2019, 134, 2375-2375.	0.6	0
17	Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A ₂ Proves Renal Origins of Urinary PGI-M and TX-M. <i>Circulation Research</i> , 2018, 122, 555-559.	2.0	28
18	Platelet responses to pharmacological and physiological interventions in middleâ€aged men with different habitual physical activity levels. <i>Acta Physiologica</i> , 2018, 223, e13028.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. <i>Platelets</i> , 2018, 29, 686-689.	1.1	16
20	96-well plate-based aggregometry. <i>Platelets</i> , 2018, 29, 650-655.	1.1	27
21	Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment" <i>Circulation Research</i> , 2018, 122, e84-e85.	2.0	3
22	Abstract 300: MicroRNA-21 Affects Platelets and Their Releasate: A Novel Mechanism for the Anti-Fibrotic Effects of MicroRNA-21 Inhibition. <i>Circulation Research</i> , 2018, 123, .	2.0	1
23	Inhibition of profibrotic microRNA-21 affects platelets and their releasate. <i>JCI Insight</i> , 2018, 3, .	2.3	30
24	Understanding the cardiovascular effects of low dose aspirin by using a platelet COX-1-/- mouse model. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-2-57.	0.0	0
25	Platelet reactivity in an elderly and healthy population. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR25-2.	0.0	0
26	Congenital Aspirin-like Defect As a Result of Autosomal Recessive Variants in PTGS1. <i>Blood</i> , 2018, 132, 1156-1156.	0.6	0
27	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 949-956.	1.1	59
28	Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 762-766.	1.0	10
29	147...Platelet cox-1 knockout mouse as a model of the effects of aspirin in the cardiovascular system. <i>Heart</i> , 2017, 103, A108.3-A109.	1.2	1
30	Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis. <i>PLoS ONE</i> , 2016, 11, e0147289.	1.1	21
31	169...Soluble Guanylate Cyclase Activators as Combination Anti-Platelet Therapy with P2Y12 Inhibitors and PDE Inhibitors: <i>In vivo</i> and <i>Ex vivo</i> Studies. <i>Heart</i> , 2016, 102, A118.2-A119.	1.2	0
32	186...Platelets as Key Regulators of Fibrin-Clot Architecture as Assessed by Fractal Analysis of Viscoelastic Properties; Effects of Standard Anti-Platelet Therapies. <i>Heart</i> , 2016, 102, A127.3-A128.	1.2	0
33	Systematic study of constitutive cyclooxygenase-2 expression: Role of NF- κ B and NFAT transcriptional pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 434-439.	3.3	140
34	Association of MicroRNAs and YRNAs With Platelet Function. <i>Circulation Research</i> , 2016, 118, 420-432.	2.0	167
35	P2Y ₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 621-633.	1.1	27
36	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. <i>Expert Review of Hematology</i> , 2016, 9, 223-225.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. <i>Blood</i> , 2015, 126, e11-e18.	0.6	28
38	213â€¦Synergy between Endothelial Mediators and P2Y12 Receptor Blockade as a Potential Determinant in Tailoring Anti-Platelet Therapy. <i>Heart</i> , 2015, 101, A116.3-A117.	1.2	0
39	158â€¦The Anti-Platelet Effectiveness of P2Y12 Receptor Blockade is Strongly Influenced by the Endothelium-Derived Mediators Nitric Oxide and Prostacyclin. <i>Heart</i> , 2015, 101, A90.2-A91.	1.2	0
40	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2122-2133.	1.1	16
41	Anti-Inflammatory and Cytoprotective Actions of Hydrogen Sulfide: Translation to Therapeutics. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 398-410.	2.5	120
42	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. <i>Blood</i> , 2014, 123, e11-e22.	0.6	60
43	Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 249-256.	1.0	43
44	Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G467-G473.	1.6	79
45	Activation of Neuronal Transient Receptor Potential Vanilloid 1 Channel Underlies 20-Hydroxyeicosatetraenoic Acidâ€œInduced Vasoactivity. <i>Hypertension</i> , 2013, 62, 426-433.	1.3	17
46	Letter by Wallace and Chan Regarding Article, â€œDrug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirinâ€œ. <i>Circulation</i> , 2013, 128, e190.	1.6	1
47	Blockade of the purinergic P2Y ₁₂ receptor greatly increases the platelet inhibitory actions of nitric oxide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15782-15787.	3.3	52
48	Aspirinâ€œtriggered 15â€œepiâ€œlipoxin A₄ predicts cyclooxygenaseâ€œ2 in the lungs of LPSâ€œtreated mice, but not in the circulation: implications for a clinical test. <i>FASEB Journal</i> , 2013, 27, 3938-3946.	0.2	20
49	Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. <i>Platelets</i> , 2012, 23, 404-408.	1.1	31
50	Distinct endothelial pathways underlie sexual dimorphism in vascular autoâ€œregulation. <i>British Journal of Pharmacology</i> , 2012, 167, 805-817.	2.7	36
51	Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. <i>Platelets</i> , 2011, 22, 485-494.	1.1	47
52	In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 552-561.	1.9	157
53	Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2103-2105.	1.9	66
54	Suppression of Endothelial P-Selectin Expression Contributes to Reduced Cell Trafficking in Females. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1075-1083.	1.1	15

#	ARTICLE	IF	CITATIONS
55	22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel. Heart, 2011, 97, e7-e7.	1.2	0
56	Endothelium-derived hyperpolarising factor (EDHF) underlies sex-differences in the pressure-induced myogenic response. FASEB Journal, 2008, 22, 719.4.	0.2	0